U.S. pharma huge copyright scrapped two experimental weight loss products last year—a the moment-day by day pill, lotiglipron, due to elevated liver enzymes in addition to a 2 times-day by day capsule, danuglipron, because of solid Negative effects—but CEO Albert Bourla has claimed the company is determined to “Engage in and acquire” in the